Inner Balance Launches Libida, a Prescription Sublingual Libido Formulation for Women

Bremelanotide + Oxytocin Combination Targets Brain-Based Pathways of Female Desire; Available Exclusively via Inner Balance Telemedicine Platform

Inner Balance, the fast-growing women’s hormone health and longevity company founded by physician and hormone specialist Dr. Sarah Daccarett, MD, today announced the launch of Libida, a prescription, sublingual, compounded formulation of bremelanotide + oxytocin, designed to restore sexual desire in women by targeting the brain’s neurochemical pathways of arousal, motivation, bonding, and pleasure.

Product Overview

Libida is formulated as a sublingual tablet that dissolves under the tongue, with onset reported at approximately 30 to 60 minutes and effects lasting up to 72 hours. The compound combines two active neuropeptides:

• Bremelanotide activates melanocortin receptors involved in sexual desire, motivation, and fantasy generation.
• Oxytocin is associated with enhanced emotional connection, reduced anxiety, and supports sexual responsiveness, amplifying the effectiveness of bremelanotide while creating a more natural, satisfying experience.

The formulation requires no injection, no refrigeration, and is not classified as a hormonal therapy. It does not contain estrogen, progesterone, or testosterone, and is not a phosphodiesterase inhibitor (the mechanism behind Viagra-class medications).

Market Context

The global female sexual dysfunction treatment market is projected to grow to approximately $1.3–1.4 billion by 2032, with peer-reviewed population-based studies estimating that approximately 40–43% of women experience some form of sexual dysfunction during their lifetime, with hypoactive sexual desire disorder (HSDD) among the most commonly reported conditions. Currently approved pharmacological treatments for HSDD — including flibanserin and bremelanotide — have faced adoption barriers due to administration complexity and side-effect profiles. Inner Balance positions Libida as a compounded sublingual alternative designed to reduce those barriers.

Executive Commentary

“Low libido is not a character flaw — it’s biology,” said Dr. Sarah Daccarett, MD, Founder and Chief Medical Officer of Inner Balance. “Women deserve a solution that reflects our actual biology. Libida doesn’t rely on hormones or blood flow the way male medications do. It supports the female brain—where desire truly lives. The synergy of bremelanotide and oxytocin allows women to experience desire, connection, and responsiveness in a way that feels authentic and intuitive.”

Distribution and Access

Libida is currently available through Inner Balance’s telemedicine platform, which provides virtual consultations with licensed clinicians specializing in women’s sexual health, discreet home delivery, and ongoing provider support via secure messaging. The platform serves women ages 21 to 64.

The company noted that Libida can be used alongside existing hormone therapy regimens and is indicated for use during perimenopause, postpartum hormonal shifts, stress-related libido changes, and age-related decline.